Investigated for treating COVID-19.
Eculizumab-aeeb (Bkemv) is biosimilar to Eculizumab (Soliris). Approved 05/28/2024
Eculizumab-aagh (Epysoli) is biosimilar to Eculizumab (Soliris). Approved 07/19/2024
- TRADE NAME: Soliris (Alexion)
- INDICATIONS: Paroxysmal nocturnal hemoglobinuria; atypical hemolytic uremic syndrome
- CLASS: Complement inhibitor, Covid-19 putative drug, Monoclonal antibody
- HALF-LIFE: ~12 days
- FDA APPROVAL DATE: 03/16/2007
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
SERIOUS MENINGOCOCCAL INFECTIONS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 07/30/2024
